



EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

MINUTES OF THE TEAMS MEETING 15th March 2023

PRESENT:

Dr L Rogan (LR)	Strategic Director of Medicines, Research and Clinical Effectiveness NHS EL ICB
Dr S Ramtoola (SR)	Consultant Physician, ELHT (Chairperson)
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Mr J Vaughan (JV)	Senior Medicines Commissioning Pharmacist NHS EL/BwD ICB
Ms Ana Batista (AB)	Medicines Information Pharmacist ELHT
Mr U Akram (UA)	Deputy Lead Pharmacist, LS CFT
Ms L Prince (LP)	Senior Medicines Management Technician, EL ICB
Dr S Jackson (SJ)	GPwSI in therapeutics
Mr Neil Fletcher (NF)	Director of Pharmacy ELHT
Dr F Shah (FS)	GP/Consultant MFOP & Diabetes

IN ATTENDANCE:

Mr W Price	Dermatology Specialist Pharmacist ELHT
Mr V Shankar	Ophthalmology Consultant
Mr M Fareeth	Acute medicine (ELHT)
Dr S Raza	Clinical Lead Intermediate service – East Lancashire Community Dermatology Service
Ms S Khan	Paediatric Pharmacist (Community Service) ELHT
Mr Akil Ahmed	Lead Paediatric Specialist Pharmacist ELHT
Dr M Lieth	Palliative Care Consultant
Mr H Hanna	Oncology Lead Pharmacist

2023/34: APOLOGIES:

Mrs H Robinson (HR)	Divisional Lead Pharmacist – MEC
Dr T MacKenzie	GP East Lancashire
Mr C Woods (CW)	Head of Contracting and Costing, Finance

2023/35: DECLARATION OF INTEREST

None declared.

2023/36: MINUTES OF FEBRUARY TEAMS MEETING:

Accepted as accurate record.

2023/37: MATTERS ARISING:

2021/101b; 2023/09: ELMMB Membership – to remain on action matrix as a standing item for feedback.



LR reported there is a planned meeting to discuss the medicines strategy across Lancashire and South Cumbria. Update/feedback to be provided when available.

2023/26: GLT2i dosing considerations according to eGFR when treating T2D, HF or CKD – Draft version. Feedback sent back to author[s]. Document will come to next meeting in April for approval.

2023/38: New Product Request

a. Aproderm Emollient Range: request from Dr Raza, Clinical Lead intermediate service, East Lancashire Community Dermatology Service to include Aproderm® cream and gel pump to formulary to add extra choice for people with badly controlled eczema. Often this cohort of patients do not use other choices e.g., colloidal oatmeal formula as often as they should resulting in poor control of their condition. It was noted that there would be no switches made to current patient regimes.

Resolved: "AproDerm® Emollient Cream and AproDerm® Gel to be added as GREEN traffic light alongside the existing options on the formulary" - **GREEN Traffic Light**

b. Mydrane 0.2mg/ml + 3.1mg/ml solution for injection (Tropicamide 0.2mg/ml, phenylephrine hydrochloride 3.1mg/ml, lidocaine hydrochloride 10mg/ml): requested for use during cataract surgery to obtain mydriasis and intraocular anaesthesia during the procedure. This is a licensed product and promotes safe surgery for use in those patients who present with poor dilation. The current product of choice is used off-license.

Resolved: Mydrane approved for use

RED Traffic Light

2023/39: Formulary Updates

a. **TheiCal** - calcium/vitamin D3 1000mg/880iu chewable tablets: request for this cost-effective option to be added to formulary as a replacement for Accrete D3 (calcium carbonate (2.5g equivalent to calcium 1000mg) / vitamin D3 880iu chewable tablets) which are currently out of stock until May 2023.

GREEN Traffic Light

b. **Ceyesto 3mg tablets** (melatonin): request for use in paediatric patients only, who are able to swallow tablets and on doses divisible by 3mg. This is a licensed product. Melatonin is currently under discussion at LSCMMG. Agreed.

AMBER Traffic Light

c. **Hypertonic sodium chloride 3%**: requested for licensed use in patients with other complex needs and excessive secretions and who are unresponsive to standard mucolytic treatment initiated by secondary care. Patients would be initiated on the treatment by ELHT consultant and with consequent follow up by physiotherapy to assess the patient response to the treatment. The prescribing would be passed out into primary care if the patient shows significant improvement. The patient would be reviewed to see if the treatment can be stepped down or stopped.

AMBER Traffic Light

d. **Degarelix**: approved for the treatment of adult male patients with advanced hormonedependent prostate cancer - patients without spinal metastases.

AMBER Traffic Light



- e. **Tolvaptan**: approved for the treatment of hyponatremia in adults, secondary to the syndrome of inappropriate antidiuretic hormone secretion (SIADH), for patients not requiring chemotherapy. **RED Traffic Light**
- f. **Duloxetine** (Cymbalta®) approved for depressive illness, generalised anxiety disorder. **GREEN Traffic Light**

Resolved: ELMMB formulary will be updated accordingly

2023/40 LSCMMG Consultations – April 2023 [deadline 06/04/23]

- a. Ogluo (glucagon): comments included to consider AMBER traffic light to discourage an increase in prescribing of the product as it is more expensive and less effective in comparison to glucagon.
- b. Iqoro (neuromuscular training device): agreed with suggested BLACK traffic light.

All documents have been circulated to appropriate directorate.

For Action: Comments to be sent to LSCMMG.

2023/41 LSCMMG Recommendations – February 2023

- a. Testosterone Hypogonadism Shared Care Guidance – updated.
- b. Denosumab Shared Care Guidance – updated.
- c. Azathioprine Mercaptopurine Shared Care Guidance – updated.
- d. Ciclosporin Shared Care Guidance – updated.
- e. Leflunomide Shared Care Guidance – updated.
- f. Methotrexate Shared Care Guidance – updated.
- g. Mycophenalte Shared Care Guidance – updated.
- h. Penicillamine Shared Care Guidance – updated.
- i. Sulfasalazine Shared Care Guidance – updated.

Resolved: items acknowledged by ELMMB. Website will be updated accordingly.

2023/42 Other Items

Use of levothyroxine 50mcg/5ml liquid formulation on exceptional circumstances. Requested by paediatric pharmacist for 8 month old child currently prescribed tablet formulation. Concerns have been raised at there appears to be poor compliance with tablets [TSH 99]. Improvement has been seen after liquid formulation was given. Liquid is currently BLACK traffic light and request is to allow GP to prescribe for child as an exception. It was suggested that ELHT give 6 month supply as an exception for this patient and then review in 6 months. Thyroxine liquid will remain BLACK on ELMMB.

Resolved: Liquid to remain BLACK traffic light, but prior approval may be sought to from ELMMB for exceptional cases.

2023/43 Other Items

Skip the dip poster: Review date to be amended and then circulated.

Resolved: Acknowledged by ELMMB and to be circulated to all matrons in ELHT wards



2023/44 NICE Guidance – February 2023

CG181: Cardiovascular disease: risk assessment and reduction, including lipid modification. Updated 10th February 2023

NG231: Barrett's oesophagus and Stage 1 oesophageal adenocarcinoma: monitoring and management. Updated 8th February 2023

Resolved: Acknowledged by ELMMB

2023/45 NICE Recommendations – February 2023

Upadactinib for treating active non-radiographic axial spondyloarthritis recommended by **NICE TA861**

ICB Commissioned, Blueteq required

Traffic Light RED

Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments is recommended by **NICE TA862**

Cancer Drug fund

Traffic Light RED

Somatrogon for treating growth disturbance in children and young people aged 3 years and over is recommended by **NICE TA863**

ICB Commissioned, Blueteq required

Traffic Light RED

Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted is recommended by **NICE TA864**

NHS England Commissioned

Traffic Light RED

Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma is recommended by **NICE TA865**

NHS England Commissioned

Traffic Light RED

Regorafenib for previously treated metastatic colorectal cancer is recommended by **NICE TA866**

NHS England Commissioned

Traffic Light RED

Mitapivat for treating pyruvate kinase deficiency (terminated appraisal) is not recommended by **NICE TA867**

Traffic Light BLACK

Vutrisiran for treating hereditary transthyretin-related amyloidosis is recommended by **NICE TA868**

NHS England Commissioned

Traffic Light RED

Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal) is not recommended by **NICE TA869**

Traffic Light BLACK

Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma is recommended by **NICE TA870**

NHS England Commissioned

Traffic Light RED



Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies is recommended by **NICE TA872**

NHS England Commissioned

Traffic Light RED

Resolved: Acknowledged by ELMMB

2023/46 NICE Highly Specialised Technologies – February 2023

HST22 Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene.

Resolved: Acknowledged by ELMMB

2023/47 EAMS (Early access to medicines scheme) – February 2023

None this month

Standing Items:

2023/48 For Action/Information: Lancashire & South Cumbria Medicines Management Group (LSCMMG)

DRAFT LSCMMG minutes 09.02.23 acknowledged.

2023/49 For Action/Information: Lancashire & South Cumbria FT Drugs and Therapeutics Committee

Minutes and open action tracker from 26th January acknowledged.

2023/50 For Action/Information: Antimicrobial Stewardship Committee (ASC)

None

January 2023 minutes not yet ratified.

2023/51 Any other Business

Suggestion for management of patients in the last days of life who take oral Methadone for opioid dependence - draft 2: presented by Dr M Lieth as a guide for GPs and to support consistent practice with the palliative care team leading or liaising with the GP where appropriate. The majority of prescribing will be undertaken by the palliative care team, who will create and record treatment plans on the EMIS system [PMR].

Resolved: Approved

2023/52 Any other business

Osimertinib – FOC scheme. Request from Hanni Hana for supply of an Astra Zeneca drug for a cancer patient who does not fit in to the commissioning guidance. Astra Zeneca have agreed to provide the drug on a compassionate indication. The chair of the cancer network was contacted to approve the request, but no response has been received. There is currently no formal process in place for approval of FOC requests via the network.

Resolved: Authorised for use via FOC scheme.



DATE OF NEXT MEETING – Wednesday 19th April 2023 12.30pm via ‘Microsoft Teams’

**ACTION SHEET FROM
EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

WEDNESDAY 22nd February 2023

MINUTE NUMBER	DESCRIPTION	ACTION	DATE
2021/101b and 2023/09	ELMMB Membership A review will be required to decide how ELMMB links with the ICS and ICB in the future and the policy for introduction of new drugs will require review as a result of that. Await full ICB structure - keep as standing item	LR/VG	Apr 23
2023/26	GLT2i dosing considerations according to eGFR when treating T2D, HF or CKD – Draft version. Version to be updated in line with NICE guidance. SJ to email comments to be reviewed by AF and bring back for approval	SJ/AF	Apr 23